Q1 2025 Earnings Estimate for Fennec Pharmaceuticals Inc (NASDAQ:FENC) Issued By Wedbush

Fennec Pharmaceuticals Inc (NASDAQ:FENC) – Investment analysts at Wedbush cut their Q1 2025 earnings per share estimates for Fennec Pharmaceuticals in a research note issued on Tuesday, May 14th. Wedbush analyst D. Nierengarten now anticipates that the company will earn $0.08 per share for the quarter, down from their previous estimate of $0.13. Wedbush has a “Outperform” rating and a $16.00 price target on the stock. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.51 per share. Wedbush also issued estimates for Fennec Pharmaceuticals’ Q2 2025 earnings at $0.09 EPS, Q3 2025 earnings at $0.12 EPS, Q4 2025 earnings at $0.13 EPS, FY2026 earnings at $2.57 EPS and FY2027 earnings at $3.01 EPS.

A number of other research analysts also recently commented on the company. Craig Hallum reduced their price target on Fennec Pharmaceuticals from $20.00 to $17.00 and set a “buy” rating for the company in a report on Wednesday. HC Wainwright reduced their target price on Fennec Pharmaceuticals from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Wednesday.

Fennec Pharmaceuticals Stock Performance

FENC stock opened at $6.98 on Thursday. Fennec Pharmaceuticals has a 1 year low of $6.30 and a 1 year high of $11.92. The firm has a market cap of $190.69 million, a P/E ratio of -11.44 and a beta of 0.45. The stock has a 50-day simple moving average of $9.97 and a 200-day simple moving average of $9.64.

Fennec Pharmaceuticals (NASDAQ:FENC) last announced its quarterly earnings results on Tuesday, May 14th. The company reported $0.41 EPS for the quarter, missing the consensus estimate of $0.49 by ($0.08). The business had revenue of $25.38 million during the quarter, compared to the consensus estimate of $10.46 million. During the same period in the previous year, the company earned ($0.23) EPS.

Insider Buying and Selling

In related news, COO Adrian Haigh sold 22,222 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $10.30, for a total value of $228,886.60. Following the sale, the chief operating officer now owns 22,222 shares of the company’s stock, valued at approximately $228,886.60. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CFO Robert Andrade sold 13,975 shares of the firm’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $11.00, for a total value of $153,725.00. Following the sale, the chief financial officer now directly owns 105,746 shares in the company, valued at approximately $1,163,206. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Adrian Haigh sold 22,222 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $10.30, for a total value of $228,886.60. Following the completion of the sale, the chief operating officer now owns 22,222 shares in the company, valued at $228,886.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 193,093 shares of company stock valued at $1,984,921. Insiders own 11.25% of the company’s stock.

Hedge Funds Weigh In On Fennec Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Allspring Global Investments Holdings LLC bought a new stake in shares of Fennec Pharmaceuticals during the 3rd quarter worth $50,000. AIGH Capital Management LLC boosted its position in shares of Fennec Pharmaceuticals by 6.9% in the third quarter. AIGH Capital Management LLC now owns 373,526 shares of the company’s stock worth $2,805,000 after buying an additional 24,069 shares during the period. Gendell Jeffrey L boosted its position in shares of Fennec Pharmaceuticals by 0.9% in the third quarter. Gendell Jeffrey L now owns 285,992 shares of the company’s stock worth $2,148,000 after buying an additional 2,579 shares during the period. Hartford Financial Management Inc. boosted its position in shares of Fennec Pharmaceuticals by 4.4% in the fourth quarter. Hartford Financial Management Inc. now owns 47,348 shares of the company’s stock worth $531,000 after buying an additional 2,000 shares during the period. Finally, Eudaimonia Advisors LLC boosted its position in shares of Fennec Pharmaceuticals by 90.8% in the fourth quarter. Eudaimonia Advisors LLC now owns 32,686 shares of the company’s stock worth $367,000 after buying an additional 15,556 shares during the period. 55.51% of the stock is currently owned by institutional investors and hedge funds.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.